A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY TO EVALUATE THE EFFECT OF FEBUXOSTAT VERSUS PLACEBO ON JOINT DAMAGE IN HYPERURICEMIC SUBJECTS WITH EARLY GOUT

被引：0
|
作者：
Dalbeth, N. [1 ]
Saag, K. [2 ]
Palmer, W. [3 ]
Choi, H. [3 ]
Li, C. [4 ]
MacDonald, P. [4 ]
Thienel, U. [4 ]
Gunawardhana, L. [4 ]
机构：
[1] Univ Auckland, Auckland, New Zealand
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[4] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.1460
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0328
引用
收藏
页码：543 / 543
页数：1
相关论文
共 50 条
  • [1] A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
    Zhang, Fengchun
    Liu, Zhichun
    Jiang, Lindi
    Zhang, Hao
    Zhao, Dongbao
    Li, Yang
    Zou, Hejian
    Wang, Xiaoyue
    Li, Xiangpei
    Shi, Bingyin
    Xu, Jianhua
    Yang, Hongjie
    Hu, Shaoxian
    Qu, Shen
    RHEUMATOLOGY AND THERAPY, 2019, 6 (04) : 543 - 557
  • [2] A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
    Fengchun Zhang
    Zhichun Liu
    Lindi Jiang
    Hao Zhang
    Dongbao Zhao
    Yang Li
    Hejian Zou
    Xiaoyue Wang
    Xiangpei Li
    Bingyin Shi
    Jianhua Xu
    Hongjie Yang
    Shaoxian Hu
    Shen Qu
    Rheumatology and Therapy, 2019, 6 : 543 - 557
  • [3] Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
    Kevin D. B. van Leeuwen
    Arthur M. Bohnen
    Rheumatology and Therapy, 2020, 7 : 215 - 216
  • [4] Comment on "A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout"
    van Leeuwen, Kevin D. B.
    Bohnen, Arthur M.
    RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 215 - 216
  • [5] Effects of Febuxostat in Early Gout A Randomized, Double-Blind, Placebo-Controlled Study
    Dalbeth, Nicola
    Saag, Kenneth G.
    Palmer, William E.
    Choi, Hyon K.
    Hunt, Barbara
    MacDonald, Patricia A.
    Thienel, Ulrich
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (12) : 2386 - 2395
  • [6] A Phase 3 Randomized, Controlled, Multicenter, Double-Blind Trial (RCT) Comparing Efficacy and Safety of Daily Febuxostat (FEB) and Allopurinol (ALLO) in Subjects with Gout
    Becker, Gout. M.
    Schumacher, H. R., Jr.
    Espinoza, L.
    Wells, A.
    MacDonald, P.
    Lloyd, E.
    Lademacher, C.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 4029 - 4029
  • [7] A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
    Wun, Ted
    Soulieres, Denis
    Frelinger, Andrew L.
    Krishnamurti, Lakshmanan
    Novelli, Enrico M.
    Kutlar, Abdullah
    Ataga, Kenneth I.
    Knupp, Charles L.
    McMahon, Lillian E.
    Strouse, John J.
    Zhou, Chunmei
    Heath, Lori E.
    Nwachuku, Chuke E.
    Jakubowski, Joseph A.
    Riesmeyer, Jeffrey S.
    Winters, Kenneth J.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [8] A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
    Ted Wun
    Denis Soulieres
    Andrew L Frelinger
    Lakshmanan Krishnamurti
    Enrico M Novelli
    Abdullah Kutlar
    Kenneth I Ataga
    Charles L Knupp
    Lillian E McMahon
    John J Strouse
    Chunmei Zhou
    Lori E Heath
    Chuke E Nwachuku
    Joseph A Jakubowski
    Jeffrey S Riesmeyer
    Kenneth J Winters
    Journal of Hematology & Oncology, 6
  • [9] Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
    Tatsuo Hosoya
    Takafumi Sano
    Tomomitsu Sasaki
    Masahiko Fushimi
    Tetsuo Ohashi
    Clinical and Experimental Nephrology, 2020, 24 : 62 - 70
  • [10] Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
    Hosoya, Tatsuo
    Sano, Takafumi
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 62 - 70
12345